期刊文献+

替格瑞洛在老年冠脉病变介入治疗中的疗效及安全性分析 被引量:16

Clinical efficacy and safety of ticagrelor in elderly patients with complex coronary disease undergoing primary percutaneous coronary intervention
下载PDF
导出
摘要 目的分析替格瑞洛在老年复杂冠脉疾病介入治疗中的疗效与安全性。方法连续纳入2013年1月-2014年12月在我院行复杂冠脉病变介入治疗的老年患者(>65岁)82例,随机分为氯吡格雷组(对照组,n=40)和替格瑞洛组(观察组,n=42),分别给予负荷量阿司匹林300 mg+氯吡格雷600 mg或阿司匹林300 mg+替格瑞洛180 mg,次日起改为维持剂量阿司匹林100 mg/d+氯吡格雷75 mg/d或阿司匹林100 mg/d+替格瑞洛180 mg/d,术后随访12个月,比较两组心血管缺血事件和主要出血事件的发生率。结果替格瑞洛组12个月主要不良心血管事件和再发心绞痛发生率明显低于氯吡格雷组(0 vs10%,4.8%vs 20.0%;P均<0.05),呼吸困难发生率明显高于氯吡格雷组(14.3%vs 0,P<0.05),而支架内血栓、主要出血事件两组差异无统计学意义。结论与氯吡格雷相比,替格瑞洛可以降低老年介入治疗心血管缺血事件发生率,尽管存在呼吸困难不良反应,但未增加出血事件,安全性良好。 Objective To analyze the clinical efficacy and safety of ticagrelor in aged patients with complex coronary disease undergoing primary percutaneous coronary intervention(PCI).Methods Eighty-two elderly patients(〉65 years old) with complex coronary disease undergoing primary PCI in our hospital from Jan.2013 to Dec.2014 were included.The patients were randomly divided into clopidogrel group(n=40) and ticagrelor group(n=42).A loading dose of aspirin 300 mg + clopidogrel 600 mg versus aspirin 300 mg + ticagrelor 180 mg were prescribed respectively for the two groups,followed by aspirin 100 mg/d + clopidogre 175 mg/d versus aspirin 100 mg/d + ticagrelor 180 mg/d for maintenance dose from the next day.All the patients were followed up for 12 months.The incidences of cardiovascular ischemic events and major bleeding events were recorded and compared.Results after a 12-month follow-up,incidences of the major adverse cardiovascular events and recurrent angina in ticagrelor group were lower than those of clopidogrel group(0 vs 10%,P〈0.05; 4.8% vs 20.0%.P〈0.05).Dyspnea were more commonly seen in ticagrelor group compared with clopidogrel group(14.3% vs 0,P〈0.05),while no significant difference were shown in severe hemorrhage and stent thrombosis between the two groups.Conclusion In elderly patients with complex coronary disease treated by PCI,ticagrelor can reduce major adverse cardiovascular events compared with clopidogrel.Though a common adverse reaction as dyspnea occurs in ticagrelor group,risk of bleeding doen't increase showing its safety.
机构地区 解放军第
出处 《解放军医学院学报》 CAS 2017年第5期423-425,共3页 Academic Journal of Chinese PLA Medical School
关键词 替格瑞洛 老年人 冠心病 介入治疗 ticagrelor aged coronary disease interventional therapy
  • 相关文献

参考文献4

二级参考文献17

  • 1中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志,2000年,28卷,10页 被引量:1
  • 2中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志,1998年,26卷,25页 被引量:1
  • 3Shirai S, Kimura T, Nobuyoshi M, et al. Impact of muhiple and long sirolimus-eluting stent implantation on 3-year clinical outcomes in the j-Cypher Registry. JACC Cardiovasc Interv, 2010, 3(2):180- 188. 被引量:1
  • 4Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT matched-cohort registry. J Am Coil Cardiol, 2007, 50(6): 501-508. 被引量:1
  • 5Shand JA, Menown IB, Storey RF. Ticagrelor: from concept to clinical evaluation. Biomark Med, 2011, 5(1): 53-62. 被引量:1
  • 6Abtahian F, Yonetsu T, Vergallo R, et al. Ticagrelor immediately prior to stenting is associated with smaller residual thrombus in patients with acute coronary syndrome. Int J Cardiol, 2013, 168(3) : 3099-3101. 被引量:1
  • 7Steg PG, Harrington RA, Emanuelsson H, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO Trial. Circulation, 2013, 128(10): 1055-1065. 被引量:1
  • 8Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus dopidogrel versus elopidogrel coronary syndrome[J]. N Engl J Med, 2009, 361(11): 1045-1057. 被引量:1
  • 9Thygesen K, Alpert .IS, White HD, et al. Joint ESC/ACCF/ AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction[J]. Fur Heart J, 2007, 28(20): 2525-2538. 被引量:1
  • 10Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents[J]. N Engl J Med, 2007, 356(10) : 1020-1029. 被引量:1

共引文献311

同被引文献144

引证文献16

二级引证文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部